INTERVIEWS

Dr. Robert Risinger, Chief Medical Officer, Neuroscience at BioXcel Therapeutics, a biopharmaceutical company that uses artificial intelligence (AI) to identify drug targets and develop drugs in neuroscience and immuno-oncology, discusses the company’s lead product, IGALMI™ (dexmedetomidine), a sublingual film used to treat agitation associated with schizophrenia or bipolar disorder and three more compounds in earlier phases of development: BXCL501, BXCL502, and +BXCL501.

Jamie McCoy, General Manager of Theranostics and Radiotherapeutics at GE HealthCare discusses theranostics and how it is changing the treatment of prostate cancer and what impact this will have on patients.

Dr. Allison McMullen, PhD, Scientific Partner for Molecular Diagnostics at Roche Diagnostics discusses a survey that shows that many Americans are confused by the differences between PCR tests and rapid antigen tests and when to use them. She talks about the importance of early diagnosis to differentiate between similar-looking respiratory viruses (including flu, COVID, and RSV), the available testing options, the latest advances in diagnostics, and additional findings from the new survey.

Prof. Arik Eisenkraft, MD., VP Clinical & Regulation at Biobeat, a digital tech company developing its proprietary data collection tools for remote patient monitoring (RPM), discusses the company’s wrist monitor and the chest monitor, both FDA-cleared to monitor stroke volume and cardiac output in addition to its previous clearances in monitoring cuffless blood pressure, blood oxygen saturation, pulse rate, respiratory rate and body temperature – 7 health metrics including the 5 vital signs, which all medical practitioners are required to assess regardless of healthcare settings. These photoplethysmography (PPG) devices are also the first and only FDA-cleared cuffless RPM solutions to screen blood pressure, a condition that often goes undetected due to insufficient blood pressure monitoring and diagnostics technologies.

David Harrell, Chairman and CEO of TranspareRX, the leading healthcare technology company bringing transparency to prescription drug pricing discusses Cuverd™ (pronounced ‘covered’) a new website and app that guides patients to get the lowest prescription cost possible.

Cardiologists at Northwestern Medicine are using AI to identify patients with advanced heart failure who require specialized care, including those who might need ventricular assistance devices or transplant.​ Dr. Faraz Ahmad, MD, MS, cardiologist and associate director of Northwestern Medicine Bluhm Cardiovascular Institute’s Center for Artificial Intelligence discusses heart failure, how AI is giving doctors advanced notice on heart failure, treatment options, and what else AI ​can ​be used for​ to help patients. For more information visit www.heart.nm.org.

Dr. Deborah Young, director of the Division of Behavioral Research for the Kaiser Permanente Southern California Department of Research & Evaluation discusses the findings of a study published by the “American Journal of Preventive Medicine,” which found that increased levels of physical activity are associated with less severe COVID-19 outcomes regardless of risk factors such as excess weight, cardiovascular disease, and hypertension.

Whether healthcare workers are on the front-line treating patients or working behind the scenes, the ability to successfully navigate change, rise above adversity, and triumph boils down to one word: RESILIENCE. Anne Grady, Keynote Speaker on Resilience and Leadership discusses resilience toolbox strategies  that can help healthcare workers to take time for self-care and avoid burnout.

Anas Younes, Senior Vice President, Head of Haematology R&D, at AstraZeneca, discusses building a broad portfolio to target different hematological cancers through diverse mechanisms and modalities, such as the next wave of IO therapies and apoptotic pathway modulating agents and his vision to develop future cornerstones for novel combination treatment strategies in hematological cancers.

Jim Geraghty discusses rare diseases and his book “Inside The Orphan Drug Revolution: The Promise of Patient-Centered Biotechnology.